Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors
January 05 2017 - 7:00AM
Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we")
(Nasdaq:SNDX), a clinical stage biopharmaceutical company focused
on developing entinostat and SNDX-6352 in multiple cancer
indications, today announced the appointment of Pierre Legault,
MBA, CA, CPA to its board of directors.
Mr. Legault has extraordinarily vast executive
management experience, including more than 35 years spent executing
creative financing strategies, driving corporate development, and
constructing value-enhancing transactions for international
biotechnology and pharmaceutical companies. In addition, Mr.
Legault has significant experience serving on the board of
directors and audit committees of public companies.
"I am very pleased to welcome Pierre Legault to
our board of directors," said Dennis Podlesak, chairman of Syndax.
"His broad global experience in drug development and
commercialization will be an important asset as we continue the
expansion of our late stage clinical pipeline and maximize our
business opportunities with entinostat. We look forward to working
with Pierre and to him contributing to our future success."
Mr. Legault currently serves on the board of
Poxel Pharmaceuticals, Iroko Pharmaceuticals and NephroGenex, and
he most recently served as board member, chairman, and audit chair,
respectively, as well as on the compensation and other committees,
of several leading companies that were successfully acquired,
notably, NPS Pharmaceuticals, Forest Laboratories, Eckerd Pharmacy
and Tobira Therapeutics. Mr. Legault’s prior executive experience
includes serving as Chief Executive Officer, President, Chief
Administrative Officer and Chief Financial Officer of several
public companies such as Eckerd Pharmacy, OSI Pharmaceuticals,
Prosidion, Ltd, and Rite Aid. He has also held several senior
positions with Sanofi-Aventis and predecessor companies, including
President of Worldwide Dermatology Operations. He studied at McGill
University, University of Montreal (HEC), and Harvard Business
School, and holds a Six Sigma Green Belt, a BAA, MBA, CA and CPA
diploma.
“I am excited to be joining Syndax as this is a
very important time for the Company with significant upcoming
clinical milestones in 2017,” said Mr. Legault. “I look forward to
working with the Syndax management team and board to help unlock
value and successfully execute on the Company’s strategic goals to
maximize shareholder value.”
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical
company focused on developing an innovative pipeline of combination
therapies in multiple cancer indications. Our lead product
candidate, entinostat, which was granted Breakthrough Therapy
designation by the FDA following positive results from our Phase 2b
clinical trial, ENCORE 301, is currently being evaluated in a Phase
3 clinical trial for advanced hormone receptor positive, human
epidermal growth factor receptor 2 negative breast cancer. Syndax
is developing entinostat, which has direct effects on both cancer
cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R
monoclonal antibody, to enhance the body's immune response on
tumors that have shown sensitivity to immunotherapy. Entinostat is
being evaluated as a combination therapeutic in Phase 1b/2 clinical
trials with Merck & Co., Inc. for non-small cell lung cancer
and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc.
and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352
is being evaluated in a single ascending dose Phase 1 clinical
trial and is expected to be developed to treat a variety of
cancers. For more information on Syndax, please visit
www.syndax.com.
Investor Contact
Heather Savelle
Argot Partners
heather@argotpartners.com
Tel 646.395.3734
Media Contact
Eliza Schleifstein
Argot Partners
eliza@argotpartners.com
Tel 973.361.1546
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Sep 2023 to Sep 2024